The global healthcare technology (HealthTech) mergers and acquisitions (M&A) ecosystem at mid-year 2026 has entered a period described by corporate development executives and private equity sponsors as "HealthTech 2.0" or "Industrial Maturity". Moving decisively beyond the venture-subsidised experimentation of the early 2020s and the severe valuation recalibrations of 2022–2023, the current transaction environment demonstrates strong capital deployment alongside target select

The European MedTech and HealthTech valuation landscape in October 2025 exhibits significant divergence by sub-sector, with a clear premium placed on innovative, high-growth, and recurring revenue business models, especially those powered by AI. Here is a breakdown of the valuation trends and multiples by sub-sector..